$AUXL - Auxilium Could Get Bought, But Not Right Away -- Market Talk
4:44 PM ET 12/6/13 | Dow Jones
16:44 EST - Auxilium (AUXL) CEO Adrian Adams is known for making his investors money, having sold three prior companies to firms like Merck (MRK) and Abbott (ABT). But don't expect an AUXL auction right away, even after it got FDA approval for Xiaflex to treat severe penis curvature. Potential buyers will want to see the rate of initial uptake and how the threat of generic competition for its testosterone gel Testim plays out, says RBC Capital's Michael Yee in an email. "I was brought to the company to create another growth story, and that's what I'm going to do," Mr. Adams said in interview. AUXL ended up 12%. (joseph.walker@wsj.com)
> Dow Jones Newswires
December 06, 2013 16:44 ET (21:44 GMT)
Copyright (c) 2013 Dow Jones & Company, Inc.
